NCT03945513View on ClinicalTrials.gov

A Multicenter, Non-Comparative Trial on the Contraceptive Efficacy, Safety, and Tolerability of LPRI-424, 13 Cycles

PHASE3CompletedINTERVENTIONAL
Enrollment

1,034

Participants

Timeline

Start Date

December 3, 2019

Primary Completion Date

June 30, 2023

Study Completion Date

September 8, 2023

Conditions
Contraception
Interventions
DRUG

LPRI424 (dienogest/ethinylestradiol)

One LPRI424 tablet once per day for 24 days followed by 4 placebo tablets for 4 days equals one cycle.

Trial Locations (1)

31406

Fellows Research Alliance, Inc., Savannah

Sponsors

Lead Sponsor

Insud Pharma

Collaborators (1)

Chemo Research
All Listed Sponsors
collaborator

Chemo Research

INDUSTRY

lead

Insud Pharma

INDUSTRY

NCT03945513 - A Multicenter, Non-Comparative Trial on the Contraceptive Efficacy, Safety, and Tolerability of LPRI-424, 13 Cycles | Biotech Hunter | Biotech Hunter